home / stock / ovid / ovid news

OVID News and Press, Ovid Therapeutics Inc. From 12/02/20

Stock Information
Company Name: Ovid Therapeutics Inc.
Stock Symbol: OVID
Market: NASDAQ
Website: ovidrx.com
Menu
OVID OVID Quote OVID Short OVID News OVID Articles OVID Message Board
Get OVID Alerts

News, Short Squeeze, Breakout and More Instantly...
OVID - CPE, FCEL, MACK and WKHS among midday movers

Gainers: NanoVibronix (NAOV) +99%.Merrimack Pharmaceuticals (MACK) +46%.Catabasis Pharmaceuticals (CATB) +44%.Tredegar (TG) +27%.Intec Pharma (NTEC) +27%.Kingsway Financial Services (KFS) +25%.Sequential Brands (SQBG) +23%.Sequans Communications (SQNS) +20%.Mmtec (MTC) +20%.Callon Petrol...
OVID - Why Ovid Therapeutics Stock Is Imploding Today

Shares of Ovid Therapeutics (NASDAQ: OVID) -- a clinical-stage biotech company -- are down by 55% as of 11:04 a.m. EST on Wednesday, after falling by as much as 56.4% earlier in the day. Investors are selling off shares of the drugmaker following negative results from a pivotal phas...

OVID - Catabasis Pharmaceuticals, iBio leads healthcare gainers; Ovid Therapeutics, Auris Medical among major losers

Gainers: Catabasis Pharmaceuticals (CATB) +44%, iBio (IBIO) +21%, Cellectar Biosciences (CLRB) +21%, Intec Pharma (NTEC) +18%, Sio Gene Therapies (SIOX) +18%.Losers: Ovid Therapeutics (OVID) -55%, Auris Medical (EARS) -35%, iRhythm Techno...

OVID - NIO Limited, Palantir Technologies leads premarket losers' pack

Ovid Therapeutics (OVID) -51% after it misses goal in Angelman syndrome treatment.FuelCell Energy (FCEL) -25% after discloses below-consensus FQ4 revenues; to launch offering.Workhorse Group (WKHS) -22% after Trucks.com reports of further delays in the ...
OVID - TG, OVID, FCEL and MESO among after-hours movers

Gainers: [[TG]] +29.6%. [[MESO]] +11.8%. [[FUBO]] +10.5%. [[VAPO]] +9.2%. [[SLQT]] +6.5%.Losers: [[OVID]] -48.7%. [[FCEL]] -16.8%. [[IRTC]] -16.1%. [[SOL]] -13.2%. [[RETA]] -9.1%. For further details see: TG, OVID, FCEL and MESO among after-hours movers

OVID - Ovid Therapeutics misses goal in Angelman syndrome treatment

Ovid Therapeutics (OVID) -44.8% post-market after saying its Phase 3 Neptune clinical trial of OV101 (gaboxadol) for the treatment of Angelman syndrome failed to meet its primary endpoint.The late-stage study was designed to assess the effects of treatment with OV101 vs. placebo over 12 weeks...

OVID - Ovid Therapeutics Announces Phase 3 NEPTUNE Clinical Trial of OV101 for the Treatment of Angelman Syndrome Did Not Meet Primary Endpoint

OV101 program in Angelman syndrome to pause pending full analysis of NEPTUNE trial and discussions with FDA Pivotal studies of OV935 (soticlestat) in Dravet syndrome and Lennox-Gastaut syndrome expected to begin in the First Half of 2021 NEW YORK, Dec. 01, 2020 (GLOBE NEWSWIRE) ...
OVID - Ovid Therapeutics to Present at the American Epilepsy Society (AES) 2020 Virtual Congress

NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that abstracts from the TAK-935/OV935 (soticlestat) clini...

OVID - Urovant Sciences, Zomedica leads healthcare gainers; Cassava Sciences, Allied Healthcare Products among major losers

Gainers: Urovant Sciences (UROV) +94%, Zomedica (ZOM) +35%, Ovid Therapeutics (OVID) +16%, Fulgent Genetics (FLGT) +12%, Myovant Sciences (MYOV) +11%.Losers: Cassava Sciences (SAVA) -26%, Allied Healthcare Products (AHPI) -24%, Biocept (BIOC) ...

OVID - Ovid Therapeutics EPS beats by $0.14, beats on revenue

Ovid Therapeutics (OVID): Q3 GAAP EPS of -$0.28 beats by $0.14.Revenue of $6.9M beats by $6.82M.Cash and cash equivalents of $86.9M.Shares -2.4%.Press Release For further details see: Ovid Therapeutics EPS beats by $0.14, beats on revenue

Previous 10 Next 10